He Liu: The Shift in China’s Medtech Sector is Truly a Game-Changer
He Liu, Chief Executive Officer at IMPELINNO GmbH, reposted from China Medtech Radar on LinkedIn:
”The shift in China’s Medtech sector is truly a game-changer, and our latest intelligence report, “The Surgeon-Engineered Solution,” captures the pivot point.
We are witnessing a fundamental move from being a cost-driven “Manufacturing” hub to a high-value “Intelligent Manufacturing” powerhouse, driven by the Med-Eng Integration model.
This means Chinese urgeons are now the primary nnovators, using their deep clinical insights to architect superior, clinical-driven devices like the ValveClamp® for TEER, MissilEX® thrombectomy and beyond, which exemplify the competitive landscape in China’s Medtech Innovation ecosystem.
I invite you to read the full analysis and engage with us: How can we best collaborate to plug into this high-velocity ecosystem? Let’s drive the future of MedTech together.”
Quoting China Medtech Radar‘s post:
”China’s medtech innovation model is undergoing a seismic shift!
The evolution of China’s medtech innovation from a cost-driven model to a clinical-led ecosystem warrants strategic consideration from the global medtech community.
We are excited to share our latest intelligence report, “The Surgeon-Engineered Solution,” which provides unique insight into the driving force behind China’s move from “Manufacturing” to “Intelligent Manufacturing.”
Key Takeaways for Global Stakeholders:
- The Surgeon as the Innovator: Chinese physicians are no longer just users; they are the source of medtech innovation. Their deep, clinical insights into unmet clinical needs are defining product development from the ground up, creating “China Solutions” to real-world problems.
- Med-Eng Integration: This is a highly efficient “Clinical-Engineering-Industry-Policy” ecosystem. It means surgeons and engineers collaborate from Day One to solve clinical pain points, leading to rapid RandD and shorter time-to-market.
- From Manufacturing to IntelligentManufacturing: This is the shift from a cost-focused, often imitative production model to a high-value, data-driven system utilizing AI and robotics to achieve breakthroughs in precision and quality.
- Real-World Success: Learn how this model has led to breakthroughs in China’s medtech like the Valve Clamp, Mitral Clip System (democratizing advanced repair), the MissilEX Intracranial Thrombectomy Device (demonstrating superior first-pass recanalization rates) and the Orthopedic Surgical Robot.
The competitive landscape in China’s medtch is being redefined.
For global medtech stakeholders, understanding this clinically-driven model is critical for successful internationalcollaboration and marketstrategy.
We invite you to read our exclusive analysis and join the conversation on fostering a collaborative future for medtechinnovation between China and the world.”
Read the full article here.
Stay updated with Hemostasis Today.
-
Apr 15, 2026, 17:30Rivaroxaban versus Aspirin after Atrial Fibrillation Ablation – Cardiology Insights and Heart Health
-
Apr 15, 2026, 17:01Emmanuel J Favaloro: A Practical Approach to Inherited and Acquired Coagulation Disorders
-
Apr 15, 2026, 16:55Chokri Ben Lamine: VA-ECMO vs VV-ECMO Thromboembolic Events – Key Clinical Pearls
-
Apr 15, 2026, 16:54Augustina Isioma Ikusemoro: The Most Misunderstood Cause of a Prolonged APTT in the Laboratory
-
Apr 15, 2026, 16:53Sickle Cell Disease Care Varies by Region – ASH
-
Apr 15, 2026, 16:40Jorge Lima։ Understanding Recurrent Pregnancy Loss
-
Apr 15, 2026, 16:26Pregnancy-Induced Rise in FIX Activity – A Challenge to International Hemophilia Guidelines – JTH
-
Apr 15, 2026, 16:18Ken Checicki: How Restoring Blood Flow Can Solve Post – DVT Complications
-
Apr 15, 2026, 16:05Alisha Tuck: Ultrasound and Anticoagulation Management in Pregnancy – Why Anticoagulation Matters?